Wave Life Sciences Ltd. (WVE) reported first-quarter 2026 financial results on Tuesday, highlighting steady clinical progress across its RNA-based therapeutic programs, including obesity, alpha-1 antitrypsin deficiency (AATD), PNPLA3- related liver disease, and Duchenne muscular dystrophy.
The company posted a net loss of $26.1 million Q1 2026, an improvement from a $46.9 million loss in the same quarter last year.
Revenue rose sharply to $38.2 million, driven by collaboration payments, compared to $9.2 million in the prior year quarter.
CEO Paul Bolno said the company is accelerating development of its lead obesity candidate WVE-007 following encouraging improvements in body composition observed in Phase 1 portion of the INLIGHT trial. Wave also expects meaningful clinical updates this quarter and throughout 2026 across its RNA editing and RNAi programs.
Pipeline Overview
WVE-007- Obesity (INLIGHT Trial)
WVE-007 is a GalNAc-siRNA candidate targeting INHBE for obesity and is being evaluated in the INLIGHT clinical program, with the Phase 2a multidose trial set to begin Q2 2026 and additional combination and maintenance studies expected to start later in 2026.
WVE-006 - Alpha-1 Antitrypsin Deficiency (RestorAATion-2)
WVE-006 is an RNA editing AIMer for AATD being studied in the RestorAATion-2 Phase 1b/2a trial, with new data from the 400 mg and 600 mg cohorts to be presented at ATS on May 18 and EASL on May 29, 2026, and regulatory feedback on accelerated approval expected mid-2026.
WVE-008- PNPLA3 I148M Liver Disease
WVE-008 is an RNA-editing AIMer targeting the PNPLA3 I148M mutation for liver disease, with a clinical trial application (CTA) filing on track for 2026.
WVE-N531- Duchenne Muscular Dystrophy (Exon 53)
WVE-N531 is an exon-skipping therapy for Duchenne muscular dystrophy, and Wave remains on track to file a New Drug Application (NDA) in 2026 seeking accelerated approval based on monthly dosing data.WVE-003- Huntington's Disease (mHTT SNP3)
WVE-003 is an allele-selective antisense candidate for Huntington's disease targeting SNP3, and Wave continues to advance multiple preclinical RNAi, RNA editing, and bifunctional oligonucleotide programs across hepatic and extra-hepatic tissues, with additional updates expected in 2026.
Wave ended the quarter with $544.6 million in cash, providing runway into the third quarter of 2028.
WVE has traded between $5.02 and $21.73 over the past year. The stock closed yesterday's trading at $7.52, up 8.36%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.